SREBF1 and type 2 diabetes mellitus: found that luteolin improved β-cell function and high insulin status in the pancreas of high-fat diet and STZ-induced T2DM rats, primarily related to increased PPAR-γ expression and decreased SREBP-1c expression, along with a reduction in inflammatory mediators such as TNF-α, IL-6, and NF-κB (166).